Inhibitory ITAMs as novel regulators of immunity
Ulrich Blank
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorPierre Launay
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorMarc Benhamou
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorRenato C. Monteiro
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorUlrich Blank
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorPierre Launay
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorMarc Benhamou
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorRenato C. Monteiro
Inserm U699, Paris, France.
Université Paris 7, Faculté de Médecine Paris Diderot – Site Xavier Bichat, Paris, France.
Search for more papers by this authorAbstract
Summary: Immune homeostasis is regulated by a finely tuned network of positive–negative regulatory mechanisms that guarantees proper surveillance avoiding hyperactivity that would lead to autoimmunity and inflammatory diseases. Immune responses involve the activation of immunoreceptors that contain tyrosine-based activation motifs (ITAMs). One arm of control involves immunoreceptor tyrosine-based inhibitory motif (ITIM)-bearing receptors, which upon co-aggregation initiate an inhibitory signal through recruitment of signal-aborting phosphatases. Recently, a new immunoregulatory function has been ascribed to ITAMs, which represent in fact dual function modules that, under specific configurations termed inhibitory ITAM (ITAMi), can propagate inhibitory signals. One paradigm is the immunoglobulin A (IgA) Fc receptor (FcαRI), which, upon interaction with IgA monomers in the absence of antigen, initiates a powerful inhibitory signal involving Src homology 2 domain-containing phosphatase 1 (SHP-1) recruitment that suppresses cell activation launched by a whole variety of heterologous receptors without co-aggregation. This explains the long known function of IgA as an anti-inflammatory isotype. The importance of this control mechanism in immune homeostasis is underlined by the high incidence of autoimmune and allergic diseases in IgA-deficient patients. ITAMi is now described for an increasing number of immunoreceptors with multiple roles in immunity. ITAMi signaling is also exploited by Escherichia coli to achieve immune evasion during sepsis. Here, we review our current understanding of ITAMi regulatory mechanisms in immune responses and discuss its role in immune homeostasis.
References
- 1
Hamerman JA,
Lanier LL.
Inhibition of immune responses by ITAM-bearing receptors.
Sci STKE
2006; 320: re1.
10.1126/stke.3202006re1 Google Scholar
- 2
Abram CL,
Lowell CA.
The expanding role for ITAM-based signaling pathways in immune cells.
Sci STKE
2007; 377: re2.
10.1126/stke.3772007re2 Google Scholar
- 3 Veillette A, Latour S, Davidson D. Negative regulation of immunoreceptor signaling. Annu Rev Immunol 2002; 20: 669–707.
- 4 Daeron M, Lesourne R. Negative signaling in Fc receptor complexes. Adv Immunol 2006; 89: 39–86.
- 5 Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306: 1517–1519.
- 6 Coggeshall KM, Nakamura K, Phee H. How do inhibitory phosphatases work? Mol Immunol 2002; 39: 521–529.
- 7 Pasquier B, et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005; 22: 31–42.
- 8 Hamerman JA, Tchao NK, Lowell CA, Lanier LL. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 2005; 6: 579–586.
- 9 Pinheiro da Silva F, et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med 2007; 13: 1368–1374.
- 10 Kanamaru Y, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol 2008; 180: 2669–2678.
- 11 Pinheiro da Silva F, Aloulou M, Benhamou M, Monteiro RC. Inhibitory ITAMs: a matter of life and death. Trends Immunol 2008; 29: 366–373.
- 12 Blasius A, Vermi W, Krug A, Facchetti F, Cella M, Colonna M. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood 2004; 103: 4201–4206.
- 13 Blasius AL, Cella M, Maldonado J, Takai T, Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006; 107: 2474–2476.
- 14 Cao W, et al. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 2006; 203: 1399–1405.
- 15 Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 2006; 177: 2051–2055.
- 16 Takaki R, Watson SR, Lanier LL. DAP12: an adapter protein with dual functionality. Immunol Rev 2006; 214: 118–129.
- 17 Turnbull IR, McDunn JE, Takai T, Townsend RR, Cobb JP, Colonna M. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J Exp Med 2005; 202: 363–369.
- 18 Turnbull IR, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006; 177: 3520–3524.
- 19 Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 2005; 106: 2076–2082.
- 20 De Magistris MT, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992; 68: 625–634.
- 21 Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993; 363: 156–159.
- 22 Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308–1310.
- 23 Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994; 79: 913–922.
- 24 Dittel BN, Stefanova I, Germain RN, Janeway CA Jr. Cross-antagonism of a T cell clone expressing two distinct T cell receptors. Immunity 1999; 11: 289–298.
- 25 Robertson JM, Evavold BD. Cutting edge: dueling TCRs: peptide antagonism of CD4+ T cells with dual antigen specificities. J Immunol 1999; 163: 1750–1754.
- 26 Kersh EN, Shaw AS, Allen PM. Fidelity of T cell activation through multistep T cell receptor zeta phosphorylation. Science 1998; 281: 572–575.
- 27 Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med 1999; 190: 1627–1636.
- 28 Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006; 6: 283–294.
- 29 Kraus M, et al. Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tail. J Exp Med 2001; 194: 455–469.
- 30 Kraus M, Saijo K, Torres RM, Rajewsky K. Ig-alpha cytoplasmic truncation renders immature B cells more sensitive to antigen contact. Immunity 1999; 11: 537–545.
- 31 Furumoto Y, Nunomura S, Terada T, Rivera J, Ra C. The FcepsilonRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004; 279: 49177–49187.
- 32 On M, Billingsley JM, Jouvin MH, Kinet JP. Molecular dissection of the FcRbeta signaling amplifier. J Biol Chem 2004; 279: 45782–45790.
- 33 Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA 1999; 96: 9792–9796.
- 34 Launay P, Patry C, Lehuen A, Pasquier B, Blank U, Monteiro RC. Alternative endocytic pathway for immunoglobulin A Fc receptors (CD89) depends on the lack of FcRgamma association and protects against degradation of bound ligand. J Biol Chem 1999; 274: 7216–7225.
- 35 Monteiro RC, Van De Winkel JGJ. IgA Fc receptors. Annu Rev Immunol 2003; 21: 177–204.
- 36 Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol 2005; 140: 478–490.
- 37 Van Epps DE, Brown SL. Inhibition of formylmethionyl-leucyl-phenylalanine-stimulated neutrophil chemiluminescence by human immunoglobulin A paraproteins. Infect Immun 1981; 34: 864–870.
- 38 Van Epps DE, Reed K, Williams RC Jr. Suppression of human PMN bactericidal activity by human IgA paraproteins. Cell Immunol 1978; 36: 363–376.
- 39 Van Epps DE, Williams RC Jr. Suppression of leukocyte chemotaxis by human IgA myeloma components. J Exp Med 1976; 144: 1227–1242.
- 40 Wilton JM. Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol 1978; 34: 423–428.
- 41 Wolf HM, Fischer MB, Puhringer H, Samstag A, Vogel E, Eibl MM. Human serum IgA downregulates the release of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6) in human monocytes. Blood 1994; 83: 1278–1288.
- 42 Wines BD, Sardjono CT, Trist HH, Lay CS, Hogarth PM. The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster. J Immunol 2001; 166: 1781–1789.
- 43 Wurzburg BA, Jardetzky TS. The IgA receptor complex: a two-for-one deal. Nat Struct Biol 2003; 10: 585–587.
- 44 Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164: 4991–4995.
- 45 Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL. Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 1998; 161: 7–10.
- 46 Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol 2003; 24: 358–363.
- 47 Reth M. Antigen receptor tail clue. Nature 1989; 338: 383–384.
- 48 Fodor S, Jakus Z, Mocsai A. ITAM-based signaling beyond the adaptive immune response. Immunol Lett 2006; 104: 29–37.
- 49 Underhill DM, Goodridge HS. The many faces of ITAMs. Trends Immunol 2007; 28: 66–73.
- 50 Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999; 72: 149–177.
- 51 Held W, Mariuzza RA. Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nat Rev Immunol 2008; 8: 269–278.
- 52 Fournier EM, et al. Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. J Immunol 2008; 181: 5350–5359.
- 53 Launay P, Lehuen A, Kawakami T, Blank U, Monteiro RC. IgA Fc receptor (CD89) activation enables coupling to syk and Btk tyrosine kinase pathways: differential signaling after IFN-gamma or phorbol ester stimulation. J Leukoc Biol 1998; 63: 636–642.
- 54 Kanamaru Y, et al. Fc alpha receptor I activation induces leukocyte recruitment and promotes aggravation of glomerulonephritis through the FcR gamma adaptor. Eur J Immunol 2007; 37: 1116–1128.
- 55 Tiwari N, et al. VAMP-8 segregates mast cell-preformed mediator exocytosis from cytokine trafficking pathways. Blood 2008; 111: 3665–3674.
- 56 Kilgore NE, Carter JD, Lorenz U, Evavold BD. Cutting edge: dependence of TCR antagonism on Src homology 2 domain-containing protein tyrosine phosphatase activity. J Immunol 2003; 170: 4891–4895.
- 57 Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003; 4: 248–254.
- 58 Ganesan LP, Fang H, Marsh CB, Tridandapani S. The protein-tyrosine phosphatase SHP-1 associates with the phosphorylated immunoreceptor tyrosine-based activation motif of Fc gamma RIIa to modulate signaling events in myeloid cells. J Biol Chem 2003; 278: 35710–35717.
- 59 Kimura T, Zhang J, Sagawa K, Sakaguchi K, Appella E, Siraganian RP. Syk-independent tyrosine phosphorylation and association of the protein tyrosine phosphatases SHP-1 and SHP-2 with the high affinity IgE receptor. J Immunol 1997; 159: 4426–4434.
- 60 Liang B, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008; 180: 5916–5926.
- 61 Torigoe C, Inman JK, Metzger H. An unusual mechanism for ligand antagonism. Science 1998; 281: 568–572.
- 62 Beaufils P, Choquet D, Mamoun RZ, Malissen B. The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J 1993; 12: 5105–5112.
- 63 Miller CL, et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995; 2: 155–166.
- 64 Fukao T, et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 2002; 3: 875–881.
- 65 Rock J, et al. CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2. Eur J Immunol 2007; 7: 3564–3575.
- 66 Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006; 125: 943–955.
- 67 Rodriguez W, et al. C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors. J Immunol 2007; 178: 530–538.
- 68 Sutterwala FS, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 1998; 188: 217–222.
- 69 Lee DJ, et al. LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol 2007; 179: 8128–8136.
- 70 Kalesnikoff J, et al. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 2001; 14: 801–811.
- 71 Asai K, et al. Regulation of mast cell survival by IgE. Immunity 2001; 14: 791–800.
- 72 Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 2004; 20: 381–392.
- 73 Kitaura J, et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA 2003; 100: 12911–12916.
- 74 Kerr MA. The structure and function of human IgA. Biochem J 1990; 271: 285–296.
- 75 Russell MW, Sibley DA, Nikolova EB, Tomana M, Mestecky J. IgA antibody as a non-inflammatory regulator of immunity. Biochem Soc Trans 1997; 25: 466–470.
- 76 Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol 2006; 208: 270–282.
- 77 Corthesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol 2007; 178: 27–32.
- 78 Nikolova EB, Russell MW. Dual function of human IgA antibodies: inhibition of phagocytosis in circulating neutrophils and enhancement of responses in IL-8-stimulated cells. J Leukoc Biol 1995; 57: 875–882.
- 79 Schaffer FM, Monteiro RC, Volanakis JE, Cooper MD. IgA deficiency. Immunodeficiency Rev 1991; 3: 15–44.
- 80 Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. J Clin Immunol 2008; 28: S56–S61.
- 81 Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 2007; 19: 646–651.
- 82 Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513–533.
- 83 Basta M, et al. F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431–438.
- 84 Debre M, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342: 945–949.
- 85 Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670–673.
- 86 Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484–486.
- 87 Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12: 688–692.
- 88 Park-Min KH, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26: 67–78.
- 89 Bayry J, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758–765.
- 90 Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571–19578.
- 91 Araki N, Johnson MT, Swanson JA. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J Cell Biol 1996; 135: 1249–1260.
- 92 Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002; 277: 32124–32132.
- 93 Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688–694.
- 94 Grande SM, Ross SR, Monroe JG. Viral immunoreceptor-associated tyrosine-based activation motifs: potential players in oncogenesis. Future Oncol 2006; 2: 301–310.
- 95 Barrow AD, Trowsdale J. You say ITAM and I say ITIM, let’s call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 2006; 36: 1646–1653.
- 96 Lanier LL. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends Cell Biol 2006; 16: 388–390.
- 97 Katz E, et al. MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture. J Exp Med 2005; 201: 431–439.
- 98 Scholle F, Bendt KM, Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000; 74: 10681–10689.
- 99 Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998; 9: 395–404.
- 100 Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1: 75–82.
- 101 Turnbull IR, Colonna M. Activating and inhibitory functions of DAP12. Nat Rev Immunol 2007; 7: 155–161.
- 102 Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 2009; 10: 340–347.
- 103 Kanamaru Y, et al. IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. Blood 2007; 109: 203–211.
- 104 Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 1999; 10: 753–760.
- 105 Imbach P, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228–1231.
- 106 Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306: 1254–1258.
- 107 Launay P, et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor–Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000; 191: 1999–2009.